AROMASIN┬« Tablets for oral administration contain 25 mg of
exemestane, an irreversible, steroidal aromatase inactivator.
AROMASIN is indicated for adjuvant treatment of postmenopausal
women with estrogen-receptor positive early breast cancer who have received two
to three years of tamoxifen and are switched to AROMASIN for completion of a
total of five consecutive years of adjuvant hormonal therapy.
AROMASIN is indicated for the treatment of advanced breast cancer in
postmenopausal women whose disease has progressed following tamoxifen therapy.
Media Articles Related to Aromasin (Exemestane)
Study links two genes to breast cancer survival
Source: Breast Cancer News From Medical News Today [2016.08.18]
Testing for the activity of two genes could pick out women who are at increased risk of dying from their breast cancers, suggests a new study of almost 2,000 patients.
New Guidelines Set Safe Surgery Margins for Some Breast Cancers
Source: MedicineNet Radiation Therapy Specialty [2016.08.16]
Title: New Guidelines Set Safe Surgery Margins for Some Breast Cancers
Category: Health News
Created: 8/15/2016 12:00:00 AM
Last Editorial Review: 8/16/2016 12:00:00 AM
Prevalence of estrogen receptor mutations in patients with metastatic breast cancer
Source: Breast Cancer News From Medical News Today [2016.08.12]
A new study published online by JAMA Oncology examines the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.
Why is breast cancer common but heart cancer rare?
Source: Cancer / Oncology News From Medical News Today [2016.08.10]
Malignant cancers strike certain organs, such as the colon or breast, more often than others.
Common virus' link to breast cancer investigated
Source: Breast Cancer News From Medical News Today [2016.08.03]
The most common virus to infect humans - EBV - plays a role in breast cancer. New research may have uncovered the mechanisms behind this relationship.
Published Studies Related to Aromasin (Exemestane)
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:
BOLERO-2 final progression-free survival analysis. 
this patient population... CONCLUSION: The addition of everolimus to exemestane markedly prolonged PFS in
Randomized phase II, double-blind, placebo-controlled study of exemestane with or
without entinostat in postmenopausal women with locally recurrent or metastatic
estrogen receptor-positive breast cancer progressing on treatment with a
nonsteroidal aromatase inhibitor. 
alone... CONCLUSION: Entinostat added to exemestane is generally well tolerated and
Health-related quality of life of patients with advanced breast cancer treated
with everolimus plus exemestane versus placebo plus exemestane in the phase 3,
randomized, controlled, BOLERO-2 trial. 
(HRQOL)... CONCLUSIONS: In patients with advanced breast cancer who develop disease
Ganitumab with either exemestane or fulvestrant for postmenopausal women with
advanced, hormone-receptor-positive breast cancer: a randomised, controlled,
double-blind, phase 2 trial. 
hormone-receptor-positive breast cancer... INTERPRETATION: Addition of ganitumab to endocrine treatment in women with
Bone density and structure in healthy postmenopausal women treated with
exemestane for the primary prevention of breast cancer: a nested substudy of the
MAP.3 randomised controlled trial. 
of potential widespread use, we examined the safety of exemestane on bone health... INTERPRETATION: 2 years of treatment with exemestane worsens age-related bone
Clinical Trials Related to Aromasin (Exemestane)
Aromasin´┐Ż Non-Interventional Study Of Early Invasive Breast Cancer Patients In China [Recruiting]
Aromasin« (Exemestane) was approved in China for adjuvant treatment of postmenopausal women
with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3
years of tamoxifen & are switched to Aromasin« for completion of a total of 5 consecutive
years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with
clinical trial waive. While Aromasin« has been used in China for adjuvant therapy of breast
cancer since then, there is currently lack of systematic collection and analysis for the
efficacy and safety data of Aromasin« adjuvant setting in Chinese population. The Aromasin«
Non-Interventional Study is being proposed to collect data systematically and to assess the
efficacy and safety of Aromasin┬« adjuvant setting in Chinese population.
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin [Terminated]
To generate the following data from patients with early breast cancer treated with Aromasin«
in the adjuvant setting in India.
- Efficacy of the treatment with Aromasin«
- Safety of the treatment with Aromasin«
A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin´┐Ż) In Postmenopausal Hr+ Patients [Terminated]
Observational survey aiming to evaluate the tolerability of Aromasin and the ways in which
it is used in clinical practice in France (as adjuvant endocrine therapy).
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding [Completed]
The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing
regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had
progressed following treatment with a nonsteroidal aromatase inhibitor (AI).
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer [Completed]
The primary goal of this 5-year study is to determine whether exemestane alone or in
combination with celecoxib decreases breast tissue density in healthy postmenopausal women
at high risk for breast cancer. Dense breast tissue seen on mammography has been linked to
an increased risk of breast cancer. The study will also examine the effects of exemestane
and celecoxib on bone density, blood hormone levels and quality of life. Exemestane,
approved by the Food and Drug Administration for treating postmenopausal women with breast
cancer, lowers the amount of estrogen in the body. Celecoxib, approved for treating
arthritis pain and for reducing the number or colon polyps in an inherited syndrome, is an
anti-inflammatory drug. Half of the women in the study will receive exemestane alone and
half will receive exemestane and celecoxib together.
In December 2004, the arm using exemestane and celecoxib was closed to accrual
Postmenopausal women who are at increased risk for developing invasive breast cancer may be
eligible to participate. Candidates are screened with breast cancer risk assessment, medical
history and physical examination, blood tests, review of medical records, if needed, breast
biopsy, and dual energy x-ray absorptiometry (DEXA) scan to assess bone density. For the
DEXA scan, the subject lies still on a table for about 30 minutes while the spine and hip
are scanned using a small amount of radiation.
Participants take exemestane in pill form once a day for 2 years. They also take calcium and
vitamin D pills daily to help protect bone health. They are followed in the clinic during
the course of the study to determine the amount of drug taken and any side effects, and for
the following tests and procedures:
- Medical evaluation and blood tests at after 1 and 3 months on study drugs
- Medical evaluation at 6 months
- Breast biopsy at screening and then at 12 months
- dual-emission x-ray absorptiometry (DEXA) scan of the spine, mammogram and routine
blood tests before starting study drugs and then yearly for 5 years.
Reports of Suspected Aromasin (Exemestane) Side Effects
Disease Progression (19),
Breast Cancer (18),
Abdominal Distension (12),
Bone Pain (11),
Headache (11), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Aromasin has an overall score of 8.50. The effectiveness score is 9 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Aromasin review by 57 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Breast Cancer|
|Dosage & duration:|| || 5mg taken 1/day for the period of 3 years|
|Other conditions:|| || under-active thyroid|
|Other drugs taken:|| || Synthroid|
|Benefits:|| || Aromasin's treatment benefits are unknown. I have not had a reoccurance of breast cancer while on the drug, though unsure we can attribute that with the drug treatment itself. Perhaps there are other positive health-related items coming into play, such as exerciase and eating habits. Not aware of any side effects or adverse reactions. Drug is very expensive, however. |
|Side effects:|| || As mentioned above, I have not had any side effects from Aromasin other than hot flashes and night sweats. These may be due to menopause rather than the treatment itself. The hot flashes have been relatively mild and can be controlled, for the most part, by limiting or removing all alcoholic beverages. |
|Comments:|| || After breast cancer treatment of chemo. and radiation I was put on Tamoxifen for several years, about 5 years. After Tamoxifen, it was recommended that I start taking Aromasin, which I have done for about 3 years. My doctor said it is not known how long women should be on Aromasin and still receeve a benefit from taking the drug.|
Aromasin review by 58 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || eostrogen-positive breast cancer|
|Dosage & duration:|| || 25mg taken daily for the period of 4 years|
|Other conditions:|| || high blood pressure|
|Other drugs taken:|| || various blood pressure medications|
|Benefits:|| || During the 4 years so far [out of 5], I have had no recurrance of the tumour and no additional tumours have been detected by ultra-sound, mammogram, and twice-yearly check-ups. Perhaps the greatest benefit is the gradual reduction in stress experienced as a result of my on-going stabilised condition after a lumpectomy.|
|Side effects:|| || I had some initial swelling of my hip, knee and ankle joints in the morning which slowly subsided during the day. The medication also aggravated the hot-flushes of the menopause, making them initially frequent and copious, and on-going for the treatment duration so far - tho with reduced frequency now in Year 4. I also experience considerable thirst.|
|Comments:|| || I was put on Aromasin after 6 months on Tamoxifen because I suffered debilitating muscle cramps on Tamoxifen as well as joint problems and extreme hot flushes. Aromasin has been kinder, and so far I have taken it daily for 4 years out of an initial 5. It may be prescribed beyond 5 years, I'm not sure. It has relatively slight side effects now but in the first 6 months I was conscious of its effects on my body - not intolerable by any means, just noticable.|
Page last updated: 2016-08-18